SCHEMBL9982909

SCHEMBL9982909

CC(=O)Nc1ccc(C)cc1N1CCC(Nc2ccccc2N)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ POLB P06746 2/20 0.40
▸ LMNA P02545 3/20 0.40
▸ GLA P06280 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PANK3 Q9H999 1/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ RPS6KB1 P23443 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KCNQ2 O43526 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9982859 0.84 MAPK1 (0.48) GAAKDM4EMAPTPOLBLMNA
SCHEMBL9982871 0.81 KMT2A (0.43) GAAMAPTPOLBLMNAPANK3
SCHEMBL8792880 0.76 POLB (0.52) GAAKDM4EMAPTPOLBLMNA
SCHEMBL12069190 0.76 CKS1B (0.45) LMNAHDAC3HDAC1HDAC2NPSR1
SCHEMBL9982556 0.75 MAPT (0.50) GAAKDM4EMAPTKMT2AMEN1
SCHEMBL16407626 0.74 MAPT (0.55) GAAKDM4EMAPTKMT2AHDAC3
SCHEMBL9982485 0.73 OPRM1 (0.46) KDM4EMAPTLMNAKMT2AMEN1
SCHEMBL27909304 0.71 MAPT (0.38) GAAMAPTLMNAKMT2AMEN1
SCHEMBL27909309 0.70 LMNA (0.38) MAPTPOLBLMNAKMT2AMEN1
SCHEMBL22605778 0.70 ALDH1A1 (0.45) KDM4EMAPTPOLBL3MBTL1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582681-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES Novartis AG (CH) 2013-04-24 — — EP disclosed
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2013-04-04 — — US disclosed
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2013-04-04 — — US disclosed
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2013-04-04 — — US disclosed
CN-102947275-A Piperidinyl-substituted 1, 3-dihydro-benzimidazol-2-ylideneamine derivatives NOVARTIS AG 2013-02-27 — — CN disclosed
WO-2011157793-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2011-12-22 — — WO disclosed
WO-2011157793-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2011-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES IGF1R, IGFBP1, IGFBP2 GAA 1377/4885KDM4E 2344/4885MAPT 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback